Showing results (151-160 of 221) with videos related to
Sort By:
Pageof 23
The Lancet. Oncology|April 8, 2014
Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trialHarpreet Wasan, Angela M Meade, Richard Adams, et al.Disability and Health Journal|November 24, 2025
Factors associated with a decline in ambulatory status among children and adults with Spina Bifida in the National Spina Bifida Patient RegistryMichael Conklin, Betsy Hopson, Jonathan Castillo, et al.Journal of Cancer Policy|June 19, 2022
Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancerRaymond H Henderson, Declan French, Ethna McFerran, et al.Bioinformatics (Oxford, England)|January 19, 2013
SBSI: an extensible distributed software infrastructure for parameter estimation in systems biologyRichard Adams, Allan Clark, Azusa Yamaguchi, et al.Eclinicalmedicine|December 25, 2024
International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome setRobert Samuel, Stephen R Knight, Richard Adams, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2017
Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal CancerMartin Scurr, Tom Pembroke, Anja Bloom, et al.British Journal of Haematology|June 17, 2026
Outcome of treatment with trametinib in adults with histiocytic neoplasms in the United KingdomRodothea Amerikanou, Talha Munir, Kristian Bowles, et al.Journal of Clinical Pathology|March 8, 2022
FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testingSusan D Richman, Gemma Hemmings, Helen Roberts, et al.BMJ Open|June 28, 2017
Talking about human papillomavirus and cancer: development of consultation guides through lay and professional stakeholder coproduction using qualitative, quantitative and secondary dataMaggie Hendry, Diana Pasterfield, Simon Gollins, et al.The Lancet. Gastroenterology & Hepatology|December 20, 2017
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trialRichard Adams, Ewan Brown, Louise Brown, et al.Pageof 23